Medpace Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

Wall Street analysts have given Medpace a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for Medpace.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings data on Sunday, April, 25th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.01 by $0.13. The company had revenue of $260 million for the quarter, compared to analysts' expectations of $266.48 million. Medpace had a net margin of 13.87% and a trailing twelve-month return on equity of 17.67%. Medpace's quarterly revenue was up 12.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.76 earnings per share.
View Medpace's earnings history.

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 92.5% and is now trading at $161.04.
View which stocks have been most impacted by COVID-19.

Medpace issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 4.240-4.420 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.370. The company issued revenue guidance of $1.09 billion-$1.15 billion, compared to the consensus revenue estimate of $1.14 billion.

4 analysts have issued 12-month price targets for Medpace's stock. Their forecasts range from $83.00 to $181.00. On average, they anticipate Medpace's share price to reach $131.80 in the next year. This suggests that the stock has a possible downside of 18.2%.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medpace include Incyte (INCY), Exact Sciences (EXAS), PPD (PPD), Charles River Laboratories International (CRL), ICON Public (ICLR), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), Precigen (PGEN), National Research (NRC), Anavex Life Sciences (AVXL), Starpharma (SPHRY), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF) and Pieris Pharmaceuticals (PIRS).
View all of MEDP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.76%), Wasatch Advisors Inc. (7.38%), Boston Trust Walden Corp (1.51%), Geode Capital Management LLC (1.38%), Northern Trust Corp (1.24%) and Standard Life Aberdeen plc (1.06%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Prudential Financial Inc., Acadian Asset Management LLC, Tributary Capital Management LLC, Los Angeles Capital Management LLC, UBS Group AG, Smith Asset Management Group LP, and Royce & Associates LP. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

MEDP stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Standard Life Aberdeen plc, BlackRock Inc., Strs Ohio, Premier Fund Managers Ltd, Geode Capital Management LLC, GW&K Investment Management LLC, and Boston Trust Walden Corp.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $161.04.

Medpace has a market capitalization of $5.79 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis.

Medpace employs 3,600 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at inv[email protected]